Azora Therapeutics, Inc. (AZR)
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
Industry: Medical - Pharmaceuticals
Azora Therapeutics, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 2.63M shares outstanding
US| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Davidson Matt | President and CEO | Grant/Award | 1.8K | -- | Oct 28, 2026 |
| Davidson Matt | President and CEO | Grant/Award | 232.4K | -- | Oct 28, 2026 |
| Davidson Matt | President and CEO | Grant/Award | 333.8K | -- | Oct 28, 2026 |
| Davidson Matt | President and CEO | Grant/Award | 31.9K | -- | Oct 28, 2026 |
| Davidson Matt | President and CEO | Grant/Award | 286.0K | -- | Oct 28, 2026 |
| Davidson Matt | President and CEO | Grant/Award | 232.4K | -- | Oct 28, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Coastlands Capital LP · joint filing· may incl. warrants· filed Jul 2026 | 373.3K | 14.2% | 13G |
 Davidson Matt President and CEO, Director | 294.1K | -- | FORM 4 |
Armistice Capital, LLC · filed May 2026 | 274.1K | 5.0% | 13G |
 Saiki Julie Chief Strategy Officer | 62.7K | -- | FORM 4 |
 Claiborne Cary J Chief Executive Officer, Director | 40.4K | -- | FORM 4 |
JANE STREET GROUP, LLC | 32.1K | -- | 13F |
CITADEL ADVISORS LLC | 29.5K | -- | 13F |
 Goodman Tony Chief Operating Officer, Director | 26.5K | -- | FORM 4 |
StoneX Group Inc. | 19.7K | -- | 13F |
UBS Group AG | 19.1K | -- | 13F |
Insiders
- Davidson MattPresident and CEO
- Young Wendy B.Director
- Coastlands Capital LP10% Owner
- Goodman TonyChief Operating Officer
- Claiborne Cary JChief Executive Officer
- Gilliland Robertson H.Director
- Shah VinayChief Financial Officer
- Schuyler KevinDirector
- Anderson J. KermitDirector
- Newman James W. Jr.Director
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
based on 2.63M shares outstanding
US30d Avg
47.55K
60d Avg
46.81K
90d Avg
57.36K